[Therapy of spastic syndromes].
D002328:Carisoprodol / Q000627:therapeutic use; D002707:Chlordiazepoxide / Q000627:therapeutic use; D002720:Chlormezanone / Q000627:therapeutic use; D002753:Chlorzoxazone / Q000627:therapeutic use; D003472:Curare / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D006140:Guaifenesin / Q000627:therapeutic use; D006801:Humans; D008615:Mephenesin / Q000627:therapeutic use; D008620:Meprobamate / Q000627:therapeutic use; D009120:Muscle Cramp / Q000188:drug therapy; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy; D009129:Muscle Tonus; D009132:Muscles / Q000503:physiopathology; D009422:Nervous System Diseases / Q000188:drug therapy*; D009468:Neuromuscular Diseases / Q000188:drug therapy; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use*; D009966:Orphenadrine / Q000627:therapeutic use; D010076:Oxazepam / Q000627:therapeutic use; D010636:Phenols / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use; D013035:Spasm / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use
D009125:Muscle Relaxants, Central; D003473:Neuromuscular Nondepolarizing Agents; D010636:Phenols; D014149:Tranquilizing Agents; D002328:Carisoprodol; D006140:Guaifenesin; D011343:Procaine; D010076:Oxazepam; D002707:Chlordiazepoxide; D008615:Mephenesin; D003472:Curare; D008620:Meprobamate; D009966:Orphenadrine; D002720:Chlormezanone; D002753:Chlorzoxazone; D003975:Diazepam
Die Therapie der spastischen Syndrome.